China NT Pharma Group Company Limited has issued a clarification regarding its major transaction involving the acquisition of 100% of the issued shares in target companies, which includes the issuance of consideration shares under a specific mandate. The company has corrected the financial figures disclosed in a previous announcement dated April 28, 2025. The figures for the financial information related to the PRC Operating Company for the years ending December 31, 2023, and December 31, 2024, should be reflected in RMB, not thousands of RMB as previously stated. The revised figures show a revenue of RMB 2,437,639 for 2023 and RMB 1,810,151 for 2024, with losses before and after taxation also updated accordingly. Other details of the transaction remain unchanged.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。